Diamyd Medical logo

Diamyd Medical jobs and careers

About Diamyd Medical

Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for the prevention and treatment of autoimmune diabetes. The investigational flagship product Diamyd® is a disease-modifying antigen-specific immunotherapy for the preservation of endogenous insulin production that has Orphan Drug Designation in the U.S. and has been granted Fast Track designation by the U.S. FDA. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and in the U.S. Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.

Founded
1994
Employees
11 to 50
Total funding
$15.5M

Leadership

The top of Diamyd Medical's org chart, with how many people report into each leader.

UHPhoto of Ulf Hannelius

Ulf Hannelius

President & CEO

25 reports

MWPhoto of Martina Widman

Martina Widman

Chief Operating Officer

14 reports

ALPhoto of Anton Lindqvist

Anton Lindqvist

Chief Scientific Officer

8 reports

NAPhoto of Niklas Axelsson

Niklas Axelsson

Chief Financial Officer